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Abstract
Background: Few published breast cancer (BC) risk prediction models consider the heterogeneity of predictor
variables between estrogen-receptor positive (ER+) and negative (ER-) tumors. Using data from two large cohorts,
we examined whether modeling this heterogeneity could improve prediction.
Methods: We built two models, for ER+ (ModelER+) and ER- tumors (ModelER-), respectively, in 281,330 women (51%
postmenopausal at recruitment) from the European Prospective Investigation into Cancer and Nutrition cohort.
Discrimination (C-statistic) and calibration (the agreement between predicted and observed tumor risks) were
assessed both internally and externally in 82,319 postmenopausal women from the Women’s Health Initiative study.
We performed decision curve analysis to compare ModelER+ and the Gail model (ModelGail) regarding their
applicability in risk assessment for chemoprevention.
Results: Parity, number of full-term pregnancies, age at first full-term pregnancy and body height were only associated
with ER+ tumors. Menopausal status, age at menarche and at menopause, hormone replacement therapy,
postmenopausal body mass index, and alcohol intake were homogeneously associated with ER+ and ER- tumors. Internal
validation yielded a C-statistic of 0.64 for ModelER+ and 0.59 for ModelER-. External validation reduced the C-statistic of
ModelER+ (0.59) and ModelGail (0.57). In external evaluation of calibration, ModelER+ outperformed the ModelGail: the former
led to a 9% overestimation of the risk of ER+ tumors, while the latter yielded a 22% underestimation of the overall BC risk.
Compared with the treat-all strategy, ModelER+ produced equal or higher net benefits irrespective of the benefit-to-harm
ratio of chemoprevention, while ModelGail did not produce higher net benefits unless the benefit-to-harm ratio was
below 50. The clinical applicability, i.e. the area defined by the net benefit curve and the treat-all and treat-none strategies,
was 12.7 × 10− 6 for ModelER+ and 3.0 × 10
− 6 for ModelGail.
Conclusions: Modeling heterogeneous epidemiological risk factors might yield little improvement in BC risk prediction.
Nevertheless, a model specifically predictive of ER+ tumor risk could be more applicable than an omnibus model in risk
assessment for chemoprevention.
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Background
Breast cancer (BC) screening and chemoprevention
strategies should prioritize women who are expected to
benefit from the interventions. Risk prediction models
could be useful assessment tools to facilitate this strat-
egy, as long as the models themselves possess sufficient
predictive power. So far, more than 20 risk prediction
models have been developed for BC since the first model
developed by Gail in 1989 [1, 2]. Initially, the Gail model
(hereinafter referred to as ModelGail) was based on age,
age at menarche and at first live birth, previous breast
biopsy, and family history of BC, yielding moderate dis-
criminatory power (C-statistic) of 0.58 in external valida-
tions [3, 4]. New predictors, such as breast density,
hormone replacement therapy (HRT), anthropometric
measures, and lifestyle factors (e.g. alcohol intake), were
continuously introduced into the succeeding models,
resulting in marginal improvements in prediction [5].
BC comprises etiologically distinct subtypes defined
by molecular factors. Hormonal and reproductive fac-
tors, such as elevated circulating sex hormone levels,
early menarche, delayed childbirth, and nulliparity, are
only or are more strongly related to increased risks of
subtypes expressing estrogen receptor (ER+) and pro-
gesterone receptor (PR+) [6]. Further, ER+ breast tu-
mors respond more favorably to hormone therapy
than ER-/PR- tumors [6–8]. It has been hypothesized
that combining etiologically distinct subtypes as one
single outcome undermines BC prediction [9]. How-
ever, most of the published BC risk prediction models
are omnibus models and only one model differentiates
risk associations by hormone receptor status [10].
In the current analysis, using data from the European
Prospective Investigation into Cancer and Nutrition
(EPIC) and the Women’s Health Initiative (WHI) study
in the USA, we examined whether modeling heteroge-
neous risk associations by ER status, which entails build-
ing ER-specific risk prediction models, could yield better
prediction of BC risk.
Methods
Study population for model derivation and internal
validation
The study population for model derivation consisted
of women recruited into the EPIC cohort from 1992
to 2000 in 10 European countries (Norway, Sweden,
Denmark, the UK, the Netherlands, Germany, France,
Spain, Italy, and Greece) [11, 12]. Women with one
or more of the following characteristics were
excluded: (1) < 40 or > 70 years of age at recruitment
(n = 49,410); (2) diagnosed with cancer before recruit-
ment (n = 39,760); and (3) no information on censor-
ing date and/or disease status (n = 142). All women
recruited in the study center of Malmö, Sweden were
also excluded due to lack of information on ER status
for all BC diagnoses (n = 14,396). After these exclu-
sions, 281,330 women (51% postmenopausal at re-
cruitment) were included in the analysis.
Study population for external validation
The WHI study was launched in 1993 and recruited
161,808 postmenopausal women aged 50–79 years into
either an observational study or one of the three clin-
ical trials that tested the health effects of HRT, a
low-fat diet, and calcium-vitamin D supplementation,
respectively [13]. For the purpose of the present study,
we excluded non-Caucasian women (n = 28,267),
women in the HRT trial (n = 27,347), women who had
mastectomy or a history of cancer at recruitment (n =
16,501), and women with incomplete information on
the risk factors considered in our models (n = 29,431),
resulting in a validation population of 82,319 women.
All women in the EPIC and WHI studies provided
written informed consent. In the WHI study, Human
Subjects Committee approval at each participating
institution was provided. The present study was
approved by the Ethical Review Board of the Inter-
national Agency for Research on Cancer (Lyon,
France).
Risk factors and disease outcomes
Among the most frequently included predictors in
current BC risk prediction models [5], the following
variables were available in EPIC and WHI, and were
therefore included in this study: menopausal status,
age at menopause, age at menarche, duration of HRT,
duration of breastfeeding, full-term pregnancy (FTP),
number of FTPs, age at first FTP, body height, body
mass index (BMI), interaction between BMI and
menopausal status, alcohol intake, and country. Table
5 in Appendix provides the coding of these predictor
variables. We retained all the women for analysis and
handled the missing values by five-time multiple im-
putations with chained equations [14]. Three pre-
dictor variablesin the Gail model were not
included in our models, i.e. family history of BC in
first-degree relatives, previous breast biopsy, and his-
tory of atypical hyperplasia. In the EPIC study, family
history of BC was only available for 49% of women,
while information on previous breast biopsy and his-
tory of atypical hyperplasia were not collected.
Sensitivity analyses that included effect modification of
parity by menopausal status in the EPIC study showed
no evidence of statistically significant interactions. Simi-
larly, no effect modifications were observed for HRT by
BMI and breastfeeding by parity. These interactions
were hence not retained further.
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Incident BC diagnoses among the EPIC women
were ascertained through national cancer registries or
a combination of health insurance records, pathology
registries, and regular questionnaire surveys. The def-
inition of positive hormone receptor status was stan-
dardized using the following criteria: ≥ 10% cells
stained, any “plus-system description”, ≥ 20 fmol/mg,
an Allred score of ≥ 3, immunoreactive score (IRS) ≥
2, or an H-score ≥ 10. Among the WHI women, cen-
trally trained, locally based physician adjudicators
verified BC diagnoses by medical record and path-
ology report review, and positive hormone receptor
status was defined as ≥ 10% cells stained [15].
Absolute risk modeling
Using the EPIC data, we fitted cause-specific
piecewise-constant hazards models [16] for ER+ and ER-
tumors separately (hereinafter referred to as ModelER+
and ModelER-). The cutoffs were placed at 45, 50, 55, 60,
65, 70, and 75 years of age. Whether a risk association is
heterogeneous by ER status was examined using the
likelihood ratio test [17].
Tumors with unknown ER status, primary cancers at
other sites, and deaths from non-cancer causes were
modelled as competing events to ER+ tumors and ER-
tumors. A Gompertz model with age as the time scale
was fitted for all these competing events combined. In
addition, ER+ and ER- tumors were considered mutually
competing.
To evaluate the improvement in risk prediction by
modeling the heterogeneous risk associations, an omni-
bus model was also fitted following the same method-
ology described above, treating ER+ and ER- tumors as
one single disease outcome.
Model validation
First, we validated our ER-specific models internally by
fivefold cross-validation [18] and then externally using
WHI data. For external validation using the WHI data,
we combined the model coefficients derived from the
EPIC women and the ER-specific baseline hazards of the
WHI women to project 5-year ER-specific absolute risks.
We calculated C-statistics to assess discriminatory ac-
curacy and the ratio of expected-to-observed number of
tumors occurring in the first 5 years (E/O) to assess
overall calibration. In the WHI women, the 5-year
absolute risk of developing BC was projected using
ModelGail, enabling us to compare the performance of
our model with that of ModelGail.
We performed decision curve analysis in the WHI
women to compare the clinical applicability of ModelER+
and ModelGail for identification of women for
chemoprevention.
Let B denote the benefit of receiving chemoprevention
for an individual who would develop BC, H the harm of
receiving chemoprevention for an individual who would
never develop BC, and pi indicates an individual risk.
The rationale of decision curve analysis is that positive
net benefits is guaranteed at the population level if che-
moprevention only covers individuals with risk projec-
tions pi above the risk threshold pt, where:
pt × B = (1 − pt) × H [19, 20].
Given the fact that quantities of B and H of chemo-
prevention remain unknown, net benefits are calcu-
lated through all the possible risk thresholds between
two extremes, i.e. zero and the maximal risk estimate,
representing a treat-all strategy and a treat-none strat-
egy, respectively. The clinical applicability of a risk
prediction model is indicated by how much the
model’s net benefit curve is above the treat-all and
treat-none strategies, i.e. the area formed by the
model’s net benefit curve and the two extreme
strategies.
Results
Cohort description
Country-specific distributions of the risk factors among
the EPIC women are shown in Table 6 in Appendix.
Distributions of the same risk factors among the WHI
women are shown in Table 7 in Appendix. During an
average follow-up period of 14.7 years, 12,067 BC cases
(7210 ER+ tumors, 1598 ER- tumors, and 3259 tumors
with unknown ER status), 16,929 primary cancers at
other sites, and 6548 deaths from non-cancer causes
were ascertained among the EPIC women, as reported in
Table 1.
The ER-specific absolute risk models
Among the risk factors with identical associations by
ER status (Table 2), being postmenopausal compared
with premenopausal at recruitment was associated
with a reduced tumor risk after controlling for age
(hazard ratio (HR) = 0.66, 95% confidence interval (CI)
= 0.60 to 0.74). For postmenopausal women, a statis-
tically significant and monotonically increasing tumor
risk was observed with older age at menopause com-
pared with reaching menopause before the age of
45 years (ptrend < 0.001). No statistically significant as-
sociation was observed for breastfeeding and breast
cancer risk among parous women. Later age at
menarche (≥ 15 vs ≤ 11 years of age) was statistically
significantly associated with decreased tumor risk
(HR = 0.85, 95% CI = 0.79 to 0.92). Duration of HRT
was statistically significantly associated with increased
breast cancer risk (ptrend < 0.001). BMI was associated
with breast cancer and exhibited a statistically significant
interaction with menopausal status: for postmenopausal
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women, HRs (95% CIs) for the BMI categories in as-
cending order were 1.11 (1.04 to 1.18), 1.21 (1.10 to
1.34), and 1.30 (1.11 to 1.53), respectively. For alcohol
intake, exceeding one drink per day, compared with
nondrinking, was statistically significantly associated
with an increased breast cancer risk.
Tests for heterogeneity showed differential risk as-
sociations for FTP, number of FTPs, age at first FTP,
body height, and country by ER status (Table 2 and
Table 8 in Appendix). Parity (one single FTP, age at
FTP ≤ 20 years) compared with nulliparity was associ-
ated with a statistically significant reduction in ER+
tumor risk (HR = 0.81, 95% CI = 0.71 to 0.91). Among
parous women, having three or more FTPs was
associated with a further risk reduction for ER+
tumors compared with one single FTP (HR = 0.87,
95% CI = 0.80 to 0.95), and delayed age at first FTP
was associated with increased ER+ tumor risk (ptrend
< 0.001). In addition, every 10-cm increment in body
height was associated with a 19% increase in ER+
tumor risk (95% CI = 1.15 to 1.24). None of these fac-
tors, however, was statistically significantly associated
with ER- tumor risk. Table 8 in Appendix shows the
coefficients for different countries by ER status. Based
on the same heterogeneous risk factor profiles, we
also estimated the risk associations using the WHI
data (Table 2), which were largely comparable to
those from the EPIC study, with the exception of age
at menarche, and especially for ER- tumors, FTP,
number of FTP, and age at first FTP.
Model validation
Table 3 shows the predictive performance of the
ER-specific models (C-statistic and E/O) corrected by
the fivefold cross-validation. ModelER+, ModelER- and
the omnibus model shared a C-statistic of 0.68. Elimin-
ation of the country effect reduced the C-statistic not-
ably to 0.64 for ModelER+, 0.59 for ModelER-, and 0.63
for the omnibus model. A minor difference in C-statistic
was observed between premenopausal and postmeno-
pausal women. The omnibus model exhibited a higher
C-statistic for ER+ than for ER- tumors (0.64 vs 0.59).
ModelER+ significantly overestimated the 5-year tumor
risk by 10% (E/O = 1.10, 95% CI = 1.05 to 1.14), particu-
larly among premenopausal women (13%). ModelER-
non-significantly underestimated the risk (E/O = 0.96,
95% CI = 0.88 to 1.05) overall and by menopausal status.
External validation with the WHI data resulted in a
C-statistic of 0.59 (95% CI = 0.58 to 0.60) for ModelER+
and 0.53 (95% CI = 0.50 to 0.57) for ModelER- (Table 4).
ModelGail yielded an overall C-statistic of 0.57 (95% CI
= 0.56 to 0.59) with a markedly lower C-statistic of 0.53
(95% CI = 0.50 to 0.57) for ER- tumors. Regarding cali-
bration, an overestimation was observed for ER+ tu-
mors (E/O = 1.09, 95% CI = 1.03 to 1.14) whereas a
statistically non-significant underestimation was
Table 1 Distribution of incident breast cancer (BC) by country, estrogen receptor (ER) status, and baseline menopausal status among
the women from the European Prospective Investigation into Cancer and Nutrition (EPIC) and Women’s Health Initiative (WHI)
studies
Number Age at
recruitment
(years)
Years
of
follow-
up
Incident
BC
Crude
incidence
rate (/105
person-
years)
Premenopausal Postmenopausal
ER+ ER- Indefinite BC ER+ ER- Indefinite BC
EPIC study
France 68,707 51.5 14.7 3386 382 1232 323 221 1776 1150 254 206 1610
Italy 27,851 52.0 15.0 1135 287 401 88 92 581 402 70 82 554
Spain 20,298 50.2 16.7 556 171 164 43 92 299 148 38 71 257
UK 35,349 52.3 16.1 1602 300 328 76 267 671 475 65 391 931
Netherlands 22,601 54.8 15.0 975 305 206 35 143 384 333 55 203 591
Greece 11,337 55.6 11.7 201 158 19 6 44 69 35 3 94 132
Germany 22,085 52.6 11.6 743 322 198 52 49 299 308 73 63 444
Sweden 9142 50.5 16.4 370 247 143 38 38 219 87 27 37 151
Denmark 29,309 56.3 16.4 1887 428 257 61 100 418 921 207 341 1469
Norway 34,651 48.0 14.1 1212 263 245 54 480 779 158 30 245 433
Total 281,330 52.1 14.7 12,067 312 3193 776 1526 5495 4017 822 1733 6572
WHI study 82,319 63.2 8.2 2951 457 – – – – 2276 421 254 2951
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Table 2 Risk associations for ER+ and ER- tumors, the EPIC study and the WHI studya
Risk factors EPIC study WHI study
ER+, n = 7210
HR (95% CI)
ER-, n = 1598
HR (95% CI)
ER+, n = 2276
HR (95% CI)
ER-, n = 421
HR (95% CI)
Menopausal status:
postmenopausalb vs premenopausal 0.66 (0.60–0.74) –
Age at menopause, years:
45.1–50.0 vs ≤ 45.0 1.16 (1.06–1.28) 1.16 (1.05–1.29)
50.1–55.0 vs ≤ 45.0 1.25 (1.13–1.38) 1.41 (1.27–1.56)
> 55.0 vs ≤ 45.0 1.41 (1.21–1.63)e 1.40 (1.20–1.62)
Breastfeeding, months:
0.1–6 vs 0 1.01 (0.95–1.08) 1.04 (0.94–1.14)
6.1–12 vs 0 0.96 (0.88–1.04) 1.04 (0.91–1.18)
> 12 vs 0 1.01 (0.93–1.11) 1.07 (0.95–1.20)
Age at menarche, years:
12 vs ≤ 11 1.06 (0.98–1.14) 0.89 (0.80–0.99)
13 vs ≤ 11 1.00 (0.93–1.07) 0.82 (0.74–0.91)
14 vs ≤ 11 0.97 (0.91–1.05) 0.86 (0.75–0.98)
≥ 15 vs ≤ 11 0.85 (0.79–0.92) 0.78 (0.67–0.91)
HRT use, years:
0.1–1.0 vs 0 1.17 (1.09–1.26) 1.01 (0.86–1.19)
1.1–2.0 vs 0 1.27 (1.15–1.40) 1.17 (0.97–1.40)
2.1–3.0 vs 0 1.39 (1.24–1.56) 1.37 (1.13–1.65)
> 3.0 vs 0 1.55 (1.44–1.66)e
1.53 (1.39–1.67)e
BMI, kg/m2:
25.0–29.9 vs < 25.0 0.99 (0.92–1.07) 1.02 (0.93–1.12)
30.0–34.9 vs < 25.0 0.97 (0.85–1.10) 1.14 (1.02–1.28)
≥ 35.0 vs < 25.0 1.12 (0.92–1.36) 1.23 (1.07–1.41)
BMI* menopausec:
1 vs 0 1.11 (1.01–1.23) –
2 vs 0 1.26 (1.07–1.47) –
3 vs 0 1.17 (0.91–1.50) –
Alcohol intake, drinks per day:
< 1.0 vs 0 1.00 (0.94–1.07) 1.08 (0.91–1.29)
1.0–1.9 vs 0 1.14 (1.05–1.24) 1.20 (0.98–1.47)
≥ 2.0 vs 0 1.22 (1.12–1.33) 1.26 (1.01–1.59)
FTPd:
Yes vs no 0.81 (0.71–0.91) 0.97 (0.76–1.24) 0.85 (0.67–1.08) 0.65 (0.37–1.14)
Number of FTP:
2 vs 1 0.99 (0.92–1.06) 1.05 (0.90–1.22) 1.14 (0.97–1.34) 1.15 (0.78–1.70)
≥ 3 vs 1 0.87 (0.80–0.95) 0.95 (0.81–1.13) 0.99 (0.84–1.17) 0.96 (0.65–1.41)
Age at 1st FTP, years:
20.1–25.0 vs ≤ 20.0 1.05 (0.97–1.14) 1.04 (0.89–1.23) 1.03 (0.89–1.20) 1.37 (0.97–1.95)
25.1–30.0 vs ≤ 20.0 1.20 (1.10–1.31) 0.93 (0.78–1.12) 1.14 (0.97–1.33) 1.34 (0.92–1.96)
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observed for ER- tumors (E/O = 0.94, 95% CI = 0.82 to
1.06). ModelGail underestimated the overall BC risk
by 22% (E/O = 0.78, 95% CI = 0.73 to 0.82). Among
the EPIC women, the overestimation of ER+ tumor
risk occurred largely in low-risk individuals (Fig. 1a);
for ER- tumor risk, overestimation was observed
mainly among low-risk individuals whereas under-
estimation was observed mainly among high-risk in-
dividuals (Fig. 1b). Among WHI women, the
overestimation by ModelER+ and the underestimation
by ModelGail were largely systematic (Fig. 1c and e).
The statistically non-significant underestimation by
ModelER- in the WHI women showed no clear pat-
tern (Fig. 1d).
Figure 2 shows the net benefit curves of ModelER+
and ModelGail. The net benefit curves of the two
models started to diverge from the treat-all strategies
at the risk threshold of 0.55%, which was roughly the
minimal risk projected by both models. ModelER+
would yield higher net benefits than both the treat-all
strategy and the treat-none strategy (denoted by the
x-axis at y = 0) if the risk threshold lay between 0.55%
and 2.5%, corresponding to an assumption that the
benefit of chemoprevention was 180 to 40 times the
Table 2 Risk associations for ER+ and ER- tumors, the EPIC study and the WHI studya (Continued)
Risk factors EPIC study WHI study
ER+, n = 7210
HR (95% CI)
ER-, n = 1598
HR (95% CI)
ER+, n = 2276
HR (95% CI)
ER-, n = 421
HR (95% CI)
30.1–35.0 vs ≤ 20.0 1.32 (1.18–1.48) 0.96 (0.75–1.23) 1.59 (1.31–1.94) 1.01 (0.58–1.75)
> 3.05 vs ≤ 20.0 1.46 (1.24–1.73)e 0.91 (0.59–1.38) 1.56 (1.16–2.09) 1.10 (0.48–2.53)
Height, per 10-cm increment 1.19 (1.15–1.24) 1.06 (0.98–1.16) 1.14 (1.06–1.22) 1.04 (0.89–1.22)
BMI body mass index, CI confidence interval, EPIC European Prospective Investigation into Cancer and Nutrition, ER estrogen receptor, FTP full-term pregnancy, HR
hazard ratio, HRT hormone replacement therapy, WHI Women’s Health Initiative
aHeterogeneous risk associations among the EPIC women were examined using the likelihood ratio test. The resulting heterogeneous risk factor profiles were
applied to the WHI women
bAge at menopause ≤ 45 years
c0: premenopausal or postmenopausal and BMI < 25 kg/m2; 1: postmenopausal and BMI 25.0–29.9 kg/m2; 2: postmenopausal and BMI 30.0–34.9 kg/m2; 3:
postmenopausal and BMI ≥ 35 kg/m2. Among postmenopausal women, the HRs (95% CIs) for BMI from low to high categories were 1.11 (1.04–1.18), 1.21
(1.10–1.34), and 1.30 (1.11–1.53)
dThe number of FTP = 1 and age at first FTP ≤ 20 years.
eptrend < 0.001
Table 3 Internal validation of the estrogen receptor (ER)-specific risk prediction models (ModelFR+ and ModelFR-) by fivefold cross-
validation, overall and by age, in the women from the European Prospective Investigation into Cancer and Nutrition (EPIC) study
ModelER+ ModelER- Omnibus model
C-statistic (95% CI)
Before eliminating country effect 0.68 (0.65–0.70) 0.68 (0.64–0.72) 0.68 (0.66–0.70)
After eliminating country effect
Overall 0.64 (0.61–0.67) 0.59 (0.54–0.64) 0.63 (0.60–0.65)
By menopausal status
Premenopausal 0.64 (0.59–0.68) 0.58 (0.51–0.66) 0.62 (0.59–0.66)
Postmenopausal 0.62 (0.59–0.66) 0.60 (0.52–0.67) 0.62 (0.59–0.65)
By ER status
ER+ – – 0.64 (0.62–0.67)
ER− – – 0.59 (0.53–0.64)
Ratio of observed–expected (95% CI)
Overall 1.10 (1.05–1.14) 0.96 (0.88–1.05) 1.07 (1.03–1.11)
By menopausal status
Premenopausal 1.13 (1.06–1.20) 0.97 (0.85–1.10) 1.09 (1.02–1.15)
Postmenopausal 1.07 (1.02–1.13) 0.96 (0.84–1.08) 1.06 (1.00–1.11)
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Table 4 External validation of the estrogen receptor (ER)-specific risk prediction models and the Gail model in women from the
Women’s Health Initiative (WHI) study
ER-specific risk prediction models ModelGail
ModelER+ ModelER−
C-statistic (95% CI)
Overall 0.59 (0.58–0.60) 0.53 (0.50–0.57) 0.57 (0.56–0.59)
By ER status
ER+ – – 0.58 (0.57–0.60)
ER− – – 0.53 (0.50–0.57)
Ratio of observed–expected (95% CI) 1.09 (1.03–1.14) 0.94 (0.82–1.06) 0.78 (0.73–0.82)
Fig. 1 Calibration of the risk prediction model of ER-positive tumors (ModelER+), risk prediction model of ER-negative tumors (ModelER-), and Gail
risk prediction model (ModelGail) by risk deciles. a ModelER+ in women from the European Prospective Investigation into Cancer and Nutrition
(EPIC); b ModelER- in the EPIC women; c ModelER+ in the women from the Women’s Health Initiative (WHI); d ModelER- in the WHI women; e
ModelGail in the WHI women
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harm. In contrast, ModelGail would yield lower net
benefits than the treat-all strategy if a risk threshold
below 2% were selected, including 1.67%, the cur-
rently adopted risk threshold for chemoprevention in
the USA, and would yield negative net benefits if a
risk threshold above 4% (i.e. benefit ≈ 25 × harm)
were selected. The clinical applicability of ModelGaili,
as indicated by the sum of Area A and Area B
shown in Fig. 2, was 3.0 × 10− 6. The clinical applic-
ability of ModelER+ was 12.7 × 10
− 6 (Area C).
Discussion
The heterogeneous risk associations in our ER-specific
risk prediction models are consistent with the estab-
lished knowledge that FTP, number of FTPs, and
delayed childbirth are associated with ER+ tumors but
not with ER- tumors [6–8]. Our study also confirms a
largescale meta-analysis of epidemiological data show-
ing that BC risk increases with prolonged duration of
HRT use [21]. Data from the WHI randomized trial
showed a statistically significant increase in the inci-
dence and mortality of invasive BC in the
estrogen-plus-progestin arm compared with the pla-
cebo arm [22, 23], whereas estrogen alone decreased
BC incidence and mortality among postmenopausal
women with prior hysterectomy [24, 25]. Stronger posi-
tive associations for estrogen plus progestin than for es-
trogen alone were reported for BC [26, 27]. In the
present study, we could not separate estrogen alone
and estrogen plus progestin due to unknown HRT com-
pounds among former users in EPIC. Among current
HRT users at baseline, use of estrogen plus progestin
was more common in EPIC than in the WHI cohort
(76% vs 44%, respectively). However, similar associa-
tions between the duration of lifetime HRT use and BC
risk were observed in both the EPIC and the WHI
study.
In ER-specific risk models, statistically significant
and homogeneous risk associations were fitted for age
at menopause and age at menarche, in line with a
pooled analysis of previous investigations where
nearly identical effects were observed for ER+ tumors
and ER- tumors [28]. The present study demonstrated
a null association between breastfeeding and BC risk,
inconsistent with previous investigations where in-
verse associations were reported [6, 8, 29]. We note
that most previous studies were case-control studies,
which were subject to recall bias. In fact, the inverse
association disappeared in some cohort studies [30,
31]. In a more recent pooled analysis, breastfeeding
was not associated with ER+ and/or PR+ tumors but
was inversely associated with ER-/PR- tumors [32].
In a pooled analysis of prospective cohort data, every
10-cm increment in body height was statistically signifi-
cantly associated with ER+ tumor risk (HR = 1.18) but
had null association with ER- tumor risk [33],
Fig. 2 Net benefit curves for the risk prediction model of ER-positive tumors (ModelER+) (black solid line) and the Gail risk prediction
model (ModelGail) (black broken line) applied to women from the Women’s Health Initiative study. Corresponding curves for the treat-all
strategy are represented in gray (solid line for all breast cancer cases, broken line for ER+ tumors only). Area A = − 7.84 × 10-6; Area
B = 1.08 × 10-5; Area C = 1.27 × 10-5
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supporting the way we modeled body height in the
present study.
Prediction of ER+ tumor risk might be practically
more useful than prediction of overall BC risk [3].
The reason for this is twofold. First, projecting
subtype-specific risks allows for accurate estimation of
the risk associations of factors that are etiologically
heterogeneous and as a result might increase the dis-
criminatory power. Second, since currently used che-
moprevention only reduces the risk of ER+ tumors
[34], there is a need for a model that can specifically
predict the risk of developing ER+ tumors.
The discriminatory accuracy of ModelER+ in internal
validation performed no better than most of the current
omnibus models using questionnaire-derived data, sug-
gesting limited improvement in discrimination after ac-
counting for etiological heterogeneity. This was not
surprising given that ER+ tumors are the dominant
subtype and the omnibus model shared nearly equiva-
lent parameters (data not shown) with ModelER+ in the
present study. According to the only study so far that
has modeled ER-specific risks, the discriminatory power
of the ER+/PR+ model was moderately higher than that
of the ER-/PR- model (0.64 vs 0.61) [10]. In that study,
risk factors with heterogeneous associations included
age, menopausal status, BMI, age at first birth, and past
use of postmenopausal HRT, and its subtype-specific
models were based on a relatively small number of tu-
mors (1281 ER+/PR+ tumors, 417 ER-/PR- tumors).
Notably, in that study there was no correction for po-
tential overfitting by either internal or external
approaches.
When externally validated in the WHI cohort, ModelER+
exhibited moderate discriminatory accuracy comparable
to that of ModelGail. Women in the USA with 5-year BC
risk of 1.67% or higher, projected by ModelGail, are consid-
ered potentially eligible for chemoprevention [35]. This
risk threshold would lead to coverage of 36,265 (44.0%)
women in our WHI validation population, of whom 1239
were subsequently diagnosed with ER+ tumors and 194
with ER- tumors. According to ModelER+, a risk threshold
of 1.97% would cover the same number of women with 16
more prospective ER+ tumors and 2 fewer prospective
ER- tumors.
The decision curve analysis provided some interest-
ing insight into the clinical applicability of ModelER+
and ModelGail. As indicated by the net benefit curves,
ModelER+ would demonstrate no advantage over the
treat-all strategy if the benefit-to-harm ratio of
chemoprevention were higher than 180, equivalent to
any risk threshold below the minimal risk projection
(≈ 0.55%), while such a boundary benefit-to-harm ra-
tio was 50 for ModelGail. Interestingly, the treat-all
strategy would even outperform ModelGail when the
risk threshold was situated at 1.67%. In contrast to
ModelGail, ModelER+ had a wider threshold range
where higher net benefits could be obtained by a
model-based decision-making than by either the
treat-all or the treat-none strategy. Considering the
unknown benefit and harm associated with chemo-
prevention, ModelER+ thus has broader applicability
than ModelGail, as indicated by the areas formed by
the two models’ net benefit curves and the two ex-
treme strategies. As shown in Fig. 2, the lowest
benefit-to-harm ratio for chemoprevention against
BC to produce a positive net benefit is 25, whereas
such a benefit-to-harm ratio for chemoprevention
against ER+ tumors is 40, suggesting that chemopre-
vention against ER+ tumors might be 1.6 times (40/25)
more efficient than chemoprevention against all types of
BC.
Among both the EPIC women and the WHI
women, ModelER+ overestimated the 5-year risk by
about 10%, possibly due to potential misspecifications
of our models, such as imperfect fit of the baseline
hazard functions (the baseline hazard estimates are
given in Table 9 in the Appendix). More importantly,
this overestimation was systematic rather than in an
overfitting pattern, i.e. underestimation occurs in
low-risk individuals and overestimation occurs in
high-risk individuals [36].
We derived ER-specific models from a large prospect-
ive cohort and validated them in another large inde-
pendent cohort for external validation. This is a strong
approach to robust parameterization and assessment of
model performance. However, some limitations
characterize the present study. Our models did not
include some established risk factors such as family
history of BC (FHBC) and previous breast biopsy, as
these variables were not available in the EPIC study.
A complete-case analysis of EPIC women with known
FHBC (n = 138,257, 49% of the sample) showed posi-
tive homogenous associations between FHBC and
tumor subtypes (HRER+ = 1.64, 95% CI = 1.49 to 1.81;
HRER- = 1.50, 95% CI = 1.23 to 1.91; pheterogeneity = 0.57),
suggesting that inclusion of this factor would increase the
predictive power of the model, though not differen-
tially across the hormonal receptor status of the tu-
mors. Another limitation of our study was the
underestimation of baseline hazards due to EPIC tu-
mors with unknown ER status, which accounted
for about 25% of BC diagnoses. Under the assump-
tion of ER-status data missing at random, parameter
estimates are expected to be unbiased, a necessary
requisite to carry out proper external validation,
whereas the underestimated baseline hazard would be
replaced with the actual baseline hazard function of
the test population.
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Conclusions
In summary, we found that modeling heterogeneous risk
associations of epidemiological factors yields little im-
provement in BC risk prediction. Nevertheless, compared
with the current omnibus models, a model specifically
predictive of ER+ tumor risk could be more applicable in
risk assessment for chemoprevention.
Appendix
Description of the Gail model
The Gail model, also known as the Breast Cancer
Risk Assessment Tool, has been adopted to estimate
the 5-year absolute risk of developing invasive breast
cancer among women aged 35 years or older. Women
with a 5-year absolute risk of 1.67% or higher as
projected by the Gail model are regarded as eligible
for chemoprevention by tamoxifen. The Gail model
includes the following predictor variables: age, ethni-
city, age at menarche, age at first live birth, number
of first-degree relatives with breast cancer, number of
previous breast biopsies, and history of atypical hyper-
plasia. The relative risks of these risk factors were es-
timated from a case-control study within the Breast
Cancer Detection Demonstration Project (BCDDP).
The baseline age-specific hazard rates were also cal-
culated from the BCDDP as the observed age-specific
hazard rates times 1 minus the population attribut-
able fraction [1]. Five-year breast cancer risk projec-
tion in the Women’s Health Initiative study using the
Gail model has been detailed elsewhere [3].
Table 5 Coding for predictor variables
Predictor variable Coding
Menopausal status 0: premenopausal
1: postmenopausal
Age at menopause 0: premenopausal or ≤ 45 years
1: 45.1–50.0 years
2: 50.1–55.0 years
3: > 55.0 years
Breastfeeding 0: parous women who never breastfed and
nulliparous women
1: 0.1–6 months
2: 6.1–12 months
3: > 12 months
Age at menarche 0: ≤ 11 years
1: 12 years
2: 13 years
3: 14 years
4: ≥ 15 years
Hormone replacement therapy (HRT) use 0: never used HRT
1: 0.1–1 year
2: 1.1–2 years
3: 2.1–3 years
4: > 3 years
Full-term pregnancy (FTP) 0: nulliparous
1: parous
Number of FTPs 0: nulliparous or 1 FTP
1: 2 FTPs
2: ≥ 3 FTPs
Age a first FTP 0: nulliparous or ≤ 20 years
1: 20.1–25.0 years
2: 25.1–30.0 years
3: 30.1–35.0 years
4: > 35.0 years
Body mass index 0: < 25.0 kg/m2
1: 25–29.9 kg/m2
2: 30–34.9 kg/m2
3: > 35.0 kg/m2
Body height per 10-cm increment Body height in centimeters divided by 10, continuous variable
Alcohol intake 0: non-drinker
1: < 1 drink/day
2: 1.0–1.9 drinks/day
3: ≥ 2 drinks/day
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Table 7 Distributions of the risk factors among the WHI women by ER status
Tumor-free ER+ ER- Indefinite
n = 79,368 n = 2276 n = 421 n = 254
Age at menopause, years:
≤ 45 26.8 22.8 25.6 25.6
45.1–50.0 34.4 31.9 38.0 35.8
50.1–55.0 30.3 34.9 30.0 28.7
> 55.0 8.5 10.4 6.4 9.9
Breastfeeding, months:
0 47.9 45.6 48.7 50.8
0.1–6.0 25.8 26.5 26.1 26.0
6.1–12.0 11.4 12.5 8.8 11.0
> 12.0 14.9 15.4 16.4 12.2
Age at menarche, years:
≤ 11 21.5 24.0 23.0 22.4
12 26.2 26.2 28.3 23.6
13 30.2 28.5 28.3 33.1
14 13.1 13.3 11.9 13.0
≥ 15 9.0 8.0 8.5 7.9
HRT use, years:
0 33.3 27.0 30.4 31.5
0.1–1.0 8.5 6.6 8.3 8.7
1.1–2.0 5.5 5.3 4.5 6.7
2.1–3.0 4.4 4.8 4.3 4.3
> 3.0 48.3 56.3 52.5 48.8
BMI, kg/m2:
< 25.0 38.8 37.8 42.3 29.5
25.0–29.9 35.2 35.2 30.1 33.9
30–34.9 16.7 17.1 18.8 21.6
≥ 35.0 9.3 9.9 8.8 15.0
Alcohol intake, drinks/day:
0 5.6 5.1 4.3 5.9
< 1.0 77.7 75.4 8.0 76.0
1.0–1.9 11.2 12.7 12.4 13.4
≥ 2.0 5.4 6.8 0.3 4.7
FTP:
0 (no) 10.3 10.0 11.2 7.1
1 (yes) 89.7 90.0 88.8 92.9
Number of FTP:
1 9.5 9.7 8.8 12.3
2 30.2 33.2 34.5 27.5
≥ 3 60.3 57.1 56.7 60.2
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Table 7 Distributions of the risk factors among the WHI women by ER status (Continued)
Tumor-free ER+ ER- Indefinite
n = 79,368 n = 2276 n = 421 n = 254
Age at 1st FTP, years:
≤ 20.0 13.0 11.0 9.9 16.5
20.1–25.0 49.4 45.6 52.4 44.9
25.1–30.0 28.5 30.0 30.2 28.8
30.1–35.0 7.0 10.3 5.6 8.5
> 35.0 2.1 3.1 1.8 1.3
Height, cm, mean 162.2 162.6 162.4 162.9
Values are percentages unless otherwise indicated
BMI body mass index, ER estrogen receptor, FTP full-term pregnancy, HRT hormone replacement therapy, WHI Women’s Health Initiative
Table 8 Coefficients for different countries by ER status in the women from the EPIC study
ModelER+ ModelER−
Coefficient P Coefficient P
France 0 – 0 –
Italy −0.186 < 0.001 −0.397 < 0.001
Spain −0.791 < 0.001 −0.806 < 0.001
UK −0.582 < 0.001 −0.842 < 0.001
Netherlands −0.513 < 0.001 −0.762 < 0.001
Greece −1.610 < 0.001 −2.023 < 0.001
Germany −0.214 < 0.001 −0.211 0.035
Sweden −0.473 < 0.001 −0.299 0.024
Denmark −0.179 < 0.001 −0.082 0.302
Norway −1.006 < 0.001 −1.244 < 0.001
ModelER+ risk prediction model of ER-positive tumors, ModelER- risk prediction model of ER-negative tumors, EPIC European Prospective Investigation into Cancer
and Nutrition, ER estrogen receptor
Table 9 Baseline piecewise constant hazard estimates for postmenopausal ER+ tumors and ER- tumors in the women from the EPIC
and the WHI studiesa
Age groups, years
40.0–44.9 45.0–49.9 50.0–54.9 55.0–59.9 60.0–64.9 65.0–69.9 70.0–74.9 ≥ 75.0
EPIC study
ER+ 30 88 152 189 227 239 233 186
ER− 19 35 44 43 42 41 40 31
WHI study
ER+ – – 126 173 185 237 243 270
ER− – – 48 50 43 50 39 50
Hazards are presented as number of tumors per 105 person-years
EPIC European Prospective Investigation into Cancer and Nutrition, WHI Women’s Health Initiative, ER estrogen receptor
aRisk factor profiles for baseline hazard: country = France (only for EPIC), menopausal status = 1 (postmenopausal), age at menopause ≤ 45 years, duration of
breastfeeding = 0, age at menarche ≤ 11 years, duration of hormone replacement therapy = 0, full-term pregnancy = 0 (nulliparous), body mass index < 25 kg/m2,
height_d10 (body height in cm divided by 10) = 16, alcohol intake (drinks/day) = 0
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